Affinity Asset Advisors LLC bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 513,420 shares of the company’s stock, valued at approximately $12,071,000. Spyre Therapeutics comprises approximately 1.4% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 19th biggest position. Affinity Asset Advisors LLC owned approximately 1.27% of Spyre Therapeutics at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC acquired a new stake in shares of Spyre Therapeutics in the second quarter worth $43,238,000. Farallon Capital Management LLC acquired a new position in Spyre Therapeutics during the 2nd quarter worth $15,658,000. Logos Global Management LP acquired a new position in Spyre Therapeutics during the 2nd quarter worth $13,518,000. First Turn Management LLC bought a new stake in Spyre Therapeutics during the second quarter valued at about $10,919,000. Finally, Great Point Partners LLC acquired a new stake in shares of Spyre Therapeutics in the second quarter valued at about $3,165,000. Institutional investors and hedge funds own 80.39% of the company’s stock.
Spyre Therapeutics Trading Down 5.8 %
Shares of Spyre Therapeutics stock opened at $28.16 on Wednesday. Spyre Therapeutics, Inc. has a twelve month low of $8.43 and a twelve month high of $47.97. The firm’s 50-day simple moving average is $27.96 and its 200-day simple moving average is $31.75.
Analyst Upgrades and Downgrades
SYRE has been the subject of several recent analyst reports. Evercore ISI began coverage on Spyre Therapeutics in a research note on Tuesday, July 16th. They set an “outperform” rating for the company. Wedbush initiated coverage on shares of Spyre Therapeutics in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $43.43.
Read Our Latest Stock Report on SYRE
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Further Reading
- Five stocks we like better than Spyre Therapeutics
- With Risk Tolerance, One Size Does Not Fit All
- Is Rivian Stock a Bargain Buy With 60% Upside Potential?
- What is the Australian Securities Exchange (ASX)
- 4 Catalysts Poised to Push Caterpillar Stock to Record Highs
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why Small-Cap Stocks Could Be Ready to Outperform After Rate Cuts
Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report).
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.